GleamWall
中文EN

NXTC NextCure, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1661059 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY29.4%
TTM EPS YoY71.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-281.1%
ROA-166.2%
ROIC (approx.)-505.2%
Asset turnover—

Leverage & solvency

Liabilities / assets43.3%
Debt / equity0.00x
Current ratio2.31x
Interest coverage—

Cash quality & payout

Operating cash flow / net income1.04x
Accruals ratio7.4%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$44.92M$41.49M
SG&A expense$12.69M$15.72M
Operating income-$57.62M-$59.75M
Income tax$0—
Net income-$55.84M-$55.65M
EBITDA-$55.42M-$56.85M
EPS (basic)-19.65-23.88
EPS (diluted)-19.65-23.88
Dividends declared per share0.000.00
Weighted avg. shares (diluted)2.84M2.33M
Balance sheet
Cash & equivalents$25.98M$27.73M
Current assets$43.75M$71.81M
PP&E, net$3.27M$5.46M
Total assets$50.18M$80.86M
Current liabilities$10.57M$9.57M
Total liabilities$15.24M$15.39M
Shareholders' equity$34.94M$65.47M
Shares outstanding3.51M2.33M
Cash flow statement
Operating cash flow-$49.61M-$40.80M
Capital expenditure—$474,000
Free cash flow—-$41.28M
Investing cash flow$25.56M$55.31M
Financing cash flow$22.31M$144,000
Depreciation & amortization$2.20M$2.90M
Stock-based compensation$2.99M$6.33M

Free plan shows the latest 2 periods; Pro shows all 8 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.